Diabetes Drug Can Control Inflammation That Causes Pain, Nerve Damage

The diabetes drug rosiglitazone (Avandia) can control inflammation that causes nerve damage and abnormal pain responses, according to a paper published in the Aug. 2011 issue of Anesthesia & Analgesia.

According to the abstract, rosiglitazone works by blocking a pathway that plays a role in the development of disabling neuropathic pain. The researchers performed several experiments to analyze how rosiglitazone affects the development of abnormal pain responses and neuropathic pain — a difficult type of pain to treat because of its association with trauma, diabetes and other conditions.

The researchers induced nerve injury in the hind legs of mice and then evaluated the effects of rosiglitazone on the development of abnormal pain responses and neuropathic pain. According to the abstract, rosiglitazone reduced the development of painful responses to stimuli that are not normally painful and decreased inflammation.

The reductions in abnormal pain responses were seen with different forms of administration of the drug, including systemic injection and local injection.

Read the current issue of Anesthesia & Analgesia.

Related Articles on Anesthesia:
Avera St. Luke's Physicians Join Avera Medical Group
Repeated Exposure to Anesthesia Drugs Could Cause Dementia
5 Updates on the Nationwide Drug Shortage


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers